Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

NCT05433935 · tracked via the Priya Life Science China tracker

Sponsor

Zhejiang University

Phase

Observational

Started

2022-07-01

Last updated

2023-01-27

Condition(s) studied

Intraductal Papillary Mucinous Neoplasm

Investigational drug(s) / intervention(s)

Observation

Observation: This is an observational study.

Study summary

This is a prospective, open large cohort study to explore biomarkers for detecting early carcinogenesis of IPMN.

Eligibility

Sex

ALL

Min age

0 Years

Max age

90 Years

Healthy volunteers

Accepted

Inclusion Criteria: * clinically diagnosed as IPMN; * without other malignant tumor; * agree to sign informed consent. Exclusion Criteria: * with mental disorders which can affect cognition and cooperation; * with serious blood diseases or taking drugs that can affect peripheral blood

Primary outcome measure(s)

The accuracy of IPMN malignant transformation — Up to 10 years

Trial sites (1)

Facility	City	Region	Status
the First Affiliated Hospital, School of Medicine, Zhejiang University	Hangzhou	Zhejiang	Recruiting

More Zhejiang University trials in China

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r B-NHL Clinical Research Recruiting

Efficacy and Safety of the Visual Bronchial Blocker for Lung Isolation Surgery Starting soon

HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients Recruiting

Perioperative Risk Factors Related to the Prognosis of Lung Transplantation: A Retrospective Study Starting soon

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer Recruiting

Other trials for the same condition

AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort Recruiting

Intra-operative Pancreatoscopy in Patients With IPMN Active, not recruiting

Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer Recruiting

Intent of Surgery for IPMN Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05433935 on ClinicalTrials.gov ↗ ← All trials in China